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Abstract
Background: The incidence of human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma
(OPSCC) is increasing. Patients with HPV-associated and HPV-unassociated OPSCC differ in many aspects, which may
also impact their diagnostic and management timelines. This study aims at studying the patient, primary health
care (PHC) and specialist-care (SC) delays and possible differences between these two patient groups in seeking
medical care.
Methods: We reviewed all new patients with OPSCC treated between 2016 and 2018 at our institute, which covers
a referral area of 1.6 million people. We collected data on patients’ symptoms and factors influencing why they
sought medical care using a patient-reported questionnaire and hospital records. We compared delays based on
patient and tumor characteristics.
Results: In our study population of 83 patients, the median patient delay was 30 days (range, 0–366), with a
median PHC delay of 15 days (range, 0 days–2.5 years), and a median SC delay of 54 days (range, 12–231). The SC
delay was further divided into diagnostic hospital delay and treatment delay, each with a median length of 16 days
(range, 0–237) and 29 days (range, 0–73), respectively. Furthermore, we found that p16 status did not associate with
delays. A longer patient delay associated with specific tumor factors, such as a larger primary tumor and a lower
UICC 7th edition stage. Patients that had multiple visits or did not have a follow-up visit scheduled at the initial
appointment had longer PHC delays. Treatment delay was significantly longer for patients scheduled for (chemo-
)radiotherapy than for those undergoing surgery with or without (chemo-)radiotherapy.
Conclusions: Although delays remained short for the majority of OPSCC patients, long delays require further
evaluation and improvement of management. Awareness of presenting symptoms among cancer risk patients and
prompt referral practice or a follow-up visit at PHC represent key factors to shortening these delays. Ultimately, the
causes for delays in SC appear multifactorial and require institutional quality control.
Keywords: Patient delay, Treatment delay, Primary health care, Diagnostic delay, Oropharyngeal cancer, Human
papillomavirus
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Introduction
The incidence of newly diagnosed oropharyngeal squa-
mous cell carcinoma (OPSCC) has increased in Western
societies due to the increase in the incidence of high-risk
human papillomavirus (HPV)–associated OPSCC [1–5].
Traditionally, OPSCC has been associated with smoking
and the heavy use of alcohol, especially the HPV-
unassociated OPSCC. Patients with HPV-associated
OPSCC, however, are typically younger, smoke less [6,
7], present with smaller primary tumors with more ad-
vanced regional lymph node spread [7–9], and have up
to a 50% better survival rate than patients with HPV-
unassociated OPSCC [10]. Therefore, these two sub-
groups may represent two distinct disease entities [11].
A marked delay before the initiation of curative treatment
among head and neck cancer (HNC) patients may lead to
tumor growth, disease advancement, and impaired prognosis
[12–20]. Treatment delay falls into two categories: patient-
and health care–related delays [21]. Health care–related
delays can be further divided into primary health care (PHC)
delay and specialist-care (SC) delay. According to a meta-
analysis by Stefanuto et al. [16], patient delay is the most im-
portant factor causing delay before treatment, a finding simi-
lar to our previous study on delays including all HNC sites
[22]. Since patient and tumor characteristics differ markedly
within the two OPSCC subgroups, it seems reasonable to as-
sume that these patients seek medical care in different ways.
This study focuses on OPSCC patients’ total delay be-
fore treatment, from the onset of initial symptoms to the
initiation of curative treatment. We were specifically in-
terested in determining how existing delays related to
patient or tumor characteristics. Therefore, we explored
whether any differences between patient groups with
HPV-associated and HPV-unassociated OPSCC existed.
Patients and methods
We identified a total of 111 patients with newly diag-
nosed OPSCC seen at the Department of
Table 1 Patient characteristics according to p16 status (n = 81 patients)
p16-positive, n = 64 (%) p16-negative, n = 17 (%) P value All, n = 83 (%)
Sex
Male 46 (71.9) 12 (70.6) 1.000 60 (72.3)
Female 18 (28.1) 5 (29.4) 23 (27.7)
Mean age (in years) 59.7 66.6 0.023 61.4
History of smoking
Never smoked 23 (35.9) 2 (11.8) < 0.001 26 (31.3)
Former smoker 33 (51.6) 5 (29.4) 39 (47.0)
Current smoker 8 (12.5) 10 (58.8) 18 (21.7)
Excessive use of alcohol
No 46 (71.9) 4 (23.5) < 0.001 52 (62.6)
Yes 11 (17.2) 6 (35.3) 17 (20.5)
Previous use 7 (10.9) 7 (41.2) 14 (16.9)
T classb
T1–2 47 (73.4) 13 (76.5) 1.000 61 (73.5)
T3–4 17 (26.6) 4 (23.5) 22 (26.5)
N classb
N+ 10 (15.6) 6 (35.3) 0.090 16 (19.3)
N0 54 (84.4) 11 (64.7) 67 (80.7)
Stageb
I-II 6 (9.4) 5 (29.4) 0.047 11 (13.3)
III-IV 58 (90.6) 12 (70.6) 72 (86.7)
Histological gradec
I 1 (1.6) 2 (12.5) 0.005 3 (3.7)
II 9 (14.3) 6 (37.5) 16 (19.8)
III 53 (84.1) 8 (50.0) 62 (76.5)
aIn 2 patients, p16 staining was unavailable
bAccording to UICC, 7th edition
cn = 81; p16-positive (n = 63), p16-negative (n = 16)
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Otorhinolaryngology – Head and Neck Surgery, Helsinki
University Hospital (Helsinki, Finland) between 14 Janu-
ary 2016 and 14 January 2018. We did not include pa-
tients with a previous HNC (n = 2) or incapable of
understanding or completing the questionnaire due to
dementia (n = 4), a language barrier (n = 3) or other rea-
sons (n = 2). Another 17 patients did not return the
questionnaire. The remaining 83 patients formed our
study cohort, the characteristics of whom appear in Ta-
bles 1 and 2. Patient and PHC delays were analyzed
among all patients regardless of treatment intent. SC
delay was analyzed only among patients with a curative
treatment intent.
Data were collected from questionnaires and from hos-
pital medical records. Patients received a questionnaire
before the initiation of definite treatment. If the patient
did not return the questionnaire within a reasonable time,
a reminder was sent via mail. Fixed-choice questions were
posed on symptoms, the time of the appearance of symp-
toms or signs, the time of the initial visit to a physician (or
dentist, hospital emergency unit or private otorhinolaryn-
gologist), the number of visits to a physician before refer-
ral to the Department of Otorhinolaryngology – Head and
Neck Surgery (Dept. ORL-HNS), the patient’s education
level, and employment. The Research Ethics Board at the
Hospital District of Helsinki and Uusimaa approved the
study design (record number: 398/13/03/02/15) and an in-
stitutional permit was granted to complete this study. All
participants in this study signed a written consent form.
The data collected from medical records included
patient-related variables such as age, sex, history of
smoking, the use of alcohol, and place of residence
(Table 2). Tumor-related variables included the tumor
site (documented using ICD-10 classification codes), the
Table 2 Delay (in days) and patient characteristics (n = 83 patients)
Number (%) Patient delay P value PHCa delay P value Specialist-care delayb P value
Age (in years) 0.370 0.974 0.253
< 46 9 (10.8) 30.0 10.0 80.0
46–65 38 (45.8) 24.0 15.0 54.5
> 65 36 (43.4) 31.0 16.0 50.0
Sex 0.795 0.305 0.806
Male 60 (72.3) 30.0 15.0 54.0
Female 23 (27.7) 26.5 21.0 50.0
History of smoking 0.327 0.799 0.069
Never smoked 26 (31.3) 30.0 13.0 62.0
Former smoker 39 (47.0) 20.0 16.0 51.0
Current smoker 18 (21.7) 39.5 15.5 49.0
Excessive use of alcohol 0.498 0.927 0.608
No 52 (62.7) 23.0 18.0 54.5
Yes 17 (20.5) 34.0 15.0 52.5
Previous use 14 (16.9) 38.5 12.5 48.0
Education 0.773 0.987 0.500
Primary school 27 (32.5) 30.5 16.0 59.0
Secondary educationc 36 (43.4) 31.0 14.0 49.0
Post-secondary educationd 20 (24.1) 24.0 20.0 52.5
Employment 0.043 0.414 0.866
Currently employed or studying 29 (34.9) 20.0 14.5 55.0
Unemployed or retired 53 (63.9) 34.0 17.0 52.5
Unknown 1 (1.2)
Place of residence 0.342 0.311 0.759
Capital area 50 (60.2) 30.0 16.0 50.0
Other 33 (39.8) 28.0 14.0 62.0
aPHC primary health care
bn = 77 patients
cSenior high school
dUniversity or university of applied sciences
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Table 3 Delay (in days) and tumor characteristics (n = 83 patients)
Number (%) Patient delay P value PHCa delay P value Specialist-care delayb P value
Site 0.216 0.130 0.632
Anterior wall 32 (38.6) 31.0 27.0 48.5
Lateral wall 47 (56.6) 16.5 13.5 55.0
Posterior wall 1 (1.2)
Superior wall 0
Overlapping sites (C10.8) 3 (3.6) 76.0 10.0 58.0
T Class, 7th and 8th UICC editionsc 0.031 0.963 0.676
T1-T2 61 (73.5) 22.5 15.5 54.5
T3-T4 22 (26.5) 59.0 15.0 50.0
N class, 7th UICC edition 0.064 0.587 0.752
N0 16 (19.3) 48.0 15.0 54.0
N1 12 (14.5) 15.0 14.0 50.0
N2a 6 (7.2) 39.0 18.0 51.5
N2b 30 (36.1) 7.0 16.0 54.5
N2c 18 (21.7) 47.0 15.0 54.0
N3 1 (1.2)
N class, 8th UICC edition 0.020 0.746 0.184
N0 16 (19.3) 48.0 15.0 54.0
N1 41 (49.4) 15.5 15.5 54.0
N2 13 (15.7) 38.5 15.0 54.5
N2a 2 (2.4) 180.5 18.0
N2b 5 (6.0) 3.0 8.0 50.0
N2c 5 (6.0) 75.0 15.0 39.0
N3 1 (1.2)
M class, 7th and 8th UICC editionsc 0.083 0.440
M0 79 (95.2) 28.0 15.0 52.5
M1 4 (4.8) 75.5 13.0
Stage, 7th UICC edition 0.047 0.939 0.644
I 2 (2.4) 125.5 76.5
II 9 (10.8) 31.0 14.0 45.0
III 11 (13.3) 13.0 15.0 59.0
IV A 54 (65.1) 23.0 17.0 54.0
IV B 3 (3.6) 59.0 9.0 37.0
IV C 4 (4.8) 75.5 13.0
Stage, 8th UICC edition 0.285 0.737 0.285
I 44 (53.0) 19.0 14.5 55.0
II 9 (10.8) 31.0 21.0 64.0
III 14 (16.9) 53.0 14.0 48.0
IV 2 (2.4) 157.0 10.0
IV A 12 (14.5) 14.0 15.0 49.5
IV B 0
IV C 2 (2.4) 75.5 13.0
p16 status 0.280 0.580 0.160
Positive 64 (77.1) 24.0 15.0 54.0
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diameter and invasion to surrounding tissues (T class),
the presence of regional and distant metastases (N and
M classes), stage, and p16 immunohistochemical stain-
ing status (Table 3). During our data collection period,
UICC released the 8th edition of the TNM classification;
therefore, variables for T, N, and M classes were
assessed using both the 7th and 8th editions [11, 23]. In
this study, we used p16 immunohistochemistry to divide
patients into p16-positive and p16-negative groups [24].
The tumor site was divided into subsites as follows: lat-
eral wall (palatine tonsils and tonsillar pillars), anterior
wall (base of the tongue and vallecula), superior wall
(soft palate and uvula), and posterior wall. The most
common tumor site was the lateral wall of the orophar-
ynx (n = 47; 57%). The majority (n = 64; 77%) of tumors
were p16-positive. Table 3 summarizes the other tumor-
related characteristics.
Definition of delay intervals
We used the following time intervals: patient delay, or
the time interval between the appearance of the first
symptom or sign of disease and the initial contact with a
health care provider; PHC delay, or the time interval
between the initial contact with a health care provider
and the referral to the Dept. ORL-HNS; and SC delay, or
the time interval between the referral to the Dept. ORL-
HNS and the initiation of curative treatment (Fig. 1).
We further divided SC delay into the diagnostic hospital
delay, or the time interval between the referral to the SC
clinic and histopathological diagnosis, and treatment
delay, or the time interval between diagnosis and the ini-
tiation of curative treatment.
We double-checked the delay data from hospital records
in order to minimize recall bias. We noted a discrepancy
in a few cases between patient-reported delay times on the
questionnaire and the delay times reported at the initial
visit to the otorhinolaryngologist. We used the latter for
our dataset, since it was documented closer to the onset
of symptoms and before the cancer diagnosis.
We used SPSS version 24 (SPSS Inc., Chicago, IL,
USA) in the statistical analysis. The distributions of de-
lays skewed to the right (most patients reported shorter
delays than average). Therefore, we employed nonpara-
metric tests in our univariate analysis. When analyzing
the delay in two independent groups, we employed the
Mann–Whitney U test; when analyzing more than two
Table 3 Delay (in days) and tumor characteristics (n = 83 patients) (Continued)
Number (%) Patient delay P value PHCa delay P value Specialist-care delayb P value
Negative 17 (20.5) 37.0 16.0 45.5
Unknown 2 (2.4)
Histological grade 0.257 0.424 0.749
I 3 (3.6) 151.0 22.0 59.0
II 16 (19.3) 28.0 34.0 56.0
III 62 (74.7) 27.0 14.5 50.0
Unknown 2 (2.4)
aPHC primary health care
bn = 77 patients
cT and M classes are similar according to the UICC 7th and 8th editions
Fig. 1 The definitions of patient, primary health care (PHC) and specialist-care (SC) delays used in our study series of OPSCC patients (n = 83)
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independent groups, we employed the Kruskal–Wallis
test. The post-hoc P values of the Kruskal–Wallis test
were Bonferroni corrected. We reported the patient de-
lays, PHC delays, and SC delays using the median values.
A multivariate linear model was employed in the covari-
ate adjusted data analysis. First, we performed a natural
log transformation for delay variables. Factors with a P <
0.2 in the univariate analysis were included in the multi-
variate analysis. Specific symptoms were not included in
the multivariate analysis since they were considered a re-
sult of the disease. The results of the multivariate ana-
lysis are reported as adjusted geometric means with 95%
confidence intervals. We considered P < 0.05 as statisti-
cally significant.
Results
Among the 83 patients in our study cohort, the median
patient delay was 30 days (mean, 56; range, 0–366). The
univariate analysis revealed that patient-related factors
had no impact on the median patient delay (Table 2). In
addition, the p16 status did no impact on patient delay.
Tumor characteristics that significantly correlated with
the patient delay included T class, N class (according to
the UICC 8th edition), and stage (according to the UICC
7th edition; Table 3). The most common symptoms in-
cluded a lump on the neck (n = 57; 69%), pain (n = 40;
48%), and problems swallowing (n = 30; 36%). Table 4
summarizes the symptoms and their relation to a delay.
The longer patient delay significantly associated with
weight loss and difficulties breathing.
The multivariate analysis revealed that patients with a
lower stage or multiple symptoms had a longer adjusted
mean patient delay (Table 5). Since T class, N class, and
M class also emerged as suitable for the multivariate
analysis, we created an alternative model including these
variables, but neither dichotomous T class (T3–4 vs T1–
2, P = 0.431), N class (N+ vs N0, P = 0.079), nor M class
(M+ vs M0, P = 0.577) significantly impacted the mean
adjusted patient delay.
The median PHC delay was 15 days (mean, 43; range,
0 days–2.5 years). The univariate analysis revealed that
neither patient- nor tumor-related factors nor symptoms
had any impact on PHC delay. Other factors that signifi-
cantly correlated with PHC delay included whether a
follow-up visit was scheduled, the number of visits to a
doctor before referral to Dept. ORL-HNS (Table 6).
According to the covariate-adjusted analysis, the number
of visits to a doctor before referral to the SC clinic
remained a significant predictor of a longer PHC delay.
The median SC delay was 54 days (mean, 59; range,
12–231). The median delay between referral to the SC
clinic and the first appointment with an otorhinolaryn-
gologist – head and neck surgeon was 7 days (mean, 12;
range, 0–153). The median delay between the referral
and diagnosis was 16 days (mean, 28; range, 0–237) and
the median treatment delay was 29 days (mean, 30;
range, 0–73). Treatment modality played a significant
role on the delay between diagnosis and the initiation of
curative treatment. Patients treated surgically, with or
without adjuvant (chemo-)radiotherapy ([C]RT), had a
significantly shorter unadjusted median treatment delay
than patients treated with definitive (C) RT (15 days vs
37 days; P < 0.001). Among surgically treated patients,
90% initiated treatment within 35 days. The correspond-
ing delay among patients treated with (C) RT reached
54 days. None of the patient- or tumor-related factors
significantly impacted SC delay. Patients reporting a
lump on the neck had a significantly shorter SC delay
(Table 4). Yet, none of the variables significantly pre-
dicted the SC delay in the covariate-adjusted analysis.
Patients (n = 6; 7%) who only received palliative treat-
ment experienced a significantly longer patient delay
(119 vs 28 days; P = 0.023) and shorter PHC delay (17 vs
1 day; P = 0.030). More specific data related to delays
among patients who received palliative treatment appear
in Supplementary Table 7.
A patient delay of more than 6months occurred in 9
cases, but no clear pattern of medical care–seeking be-
havior emerged (Supplementary Table 8). A PHC delay
of more than 3months occurred in 8 cases. In 4 of those
cases, the referral to SC was delayed because of a false
benign finding upon ultrasound or a fine-needle biopsy
result (Supplementary Table 9).
We also reviewed patient data (n = 28) among those
who did not complete the questionnaire. We found no
difference in the age and sex distributions among pa-
tients who completed the questionnaire (n = 83) com-
pared with patients who did not (n = 28). Patients who
did not complete the questionnaire had a generally lar-
ger primary tumor (T3–4; 39.3% vs 26.5%) and more ad-
vanced stage according to UICC 8th edition (stage III–
IV; 42.8% vs 20.3%). Furthermore, HPV-unassociated
OPSCC was more prevalent in the no questionnaire pa-
tient group (39.3% vs 20.5%) and more patients received
palliative treatment (25.0% vs 7.2%).
Discussion
Patient, PHC, and SC all influence the length of delay
between the first symptoms and the initiation of curative
treatment. In our study cohort of 83 OPSCC patients,
the most important factors influencing delays before
treatment were the tumor stage, the number of present-
ing symptoms, and the number of visits to a doctor be-
fore a referral to the Dept. ORL-HNS. Interestingly, p16
status played no role on that delay, although distinctive
differences between two patient groups emerged regard-
ing patient age, smoking status, alcohol use, tumor stage
and the histological grade.
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Table 4 Delay (in days) and symptoms (n = 83 patients)
Number (%) Patient delay P value PHCa delay P value Specialist-care delayb P value
Lump on the neck 0.130 0.764 0.029
No 26 (31.3) 31.0 16.0 64.0
Yes 57 (68.7) 24.0 15.0 49.5
Pain 0.526 0.898 0.345
No 43 (51.8) 22.5 15.0 55.0
Yes 40 (48.2) 37.0 16.0 49.5
Problems swallowing 0.296 0.101 0.268
No 53 (63.9) 24.0 11.0 50.0
Yes 30 (36.1) 42.0 20.0 60.5
Hoarseness 0.149 0.683 0.252
No 70 (84.3) 24.0 15.0 50.0
Yes 13 (15.7) 68.5 18.0 60.5
Ulcer or other lesion 0.661 0.633 0.886
No 70 (84.3) 29.0 15.0 51.0
Yes 13 (15.7) 39.0 20.0 55.0
Weight loss 0.012 0.837 0.391
No 74 (89.2) 24.0 15.0 52.5
Yes 9 (10.8) 75.5 16.0 69.0
Bleeding 0.959 0.491 0.155
No 79 (95.2) 30.0 15.0 54.0
Yes 4 (4.8) 28.5 26.0 41.5
Difficulty breathing 0.007 0.075 0.688
No 79 (95.2) 29.0 15.0 51.0
Yes 4 (4.8) 151.0 35.0 64.0
Facial swelling 0.583 0.223
No 81 (97.6) 30.0 15.5 52.5
Yes 2 (2.4) 51.5 5.0
Visual impairment 0.627 0.916
No 82 (98.8) 30.0 15.0 54.0
Yes 1 (1.2) 9.0 19.0
Other symptoms 16 (19.3)
Pain intensity 0.791 0.345 0.561
No pain 42 (50.6) 23.0 15.0 54.5
Mild or moderatec 29 (34.9) 39.5 14.5 49.5
Severed 12 (14.5) 21.0 34.5 54.0
Number of different symptoms 0.021 0.669 0.652
One 28 (33.7) 14.0 10.0 50.0
Two 25 (30.1) 30.5 15.5 54.0
Three or more 30 (36.1) 59.0 17.5 53.5
aPHC primary health care
bn = 77 patients
cNo need for regular painkillers
dRegular painkillers needed
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Table 5 Multivariate linear model for variables predicting patient delay, primary health-care delay, specialist delay, and total delay
Patient delay Primary health-care delay Specialist delay
Geometric
mean
95% CI P
value
Geometric
mean
95% CI P value Geometric
mean
95% CI P
value
History of smoking
Never smoked 60.8 47.8 77.5 0.145
Former smoker 48.9 39.8 60.1
Current smoker 44.4 32.4 61.0
Employment
Currently employed or
studying
34.5 10.8 110.3 0.146
Unemployed or retired 61.9 25.0 153.2
Site
Anterior wall 10.3 2.8 37.8 0.143
Lateral wall 5.6 1.6 19.4
T Class, 7th and 8th UICC editions
T1-T2
T3-T4
N class, 8th UICC edition
N0 52.4 39.6 69.1 0.727
N+ 49.6 41.8 58.8
Stage, 7th UICC edition
I-II 97.5 25.6 372.0 0.009
III-IV 21.9 9.6 49.8
p16 status
Positive 53.7 43.0 67.1 0.544
Negative 48.3 37.1 62.9
Histological grade
I
II
III
Number of different symptoms
One 32.7 10.8 99.0 0.047*
Two 34.0 10.7 108.1
Three or more 88.9 31.9 247.9
Initial place of visit
GP, dentist, or hospital emergency 11.8 4.1 25.8 0.164
Private otolaryngologist 4.9 1.0 24.3
Was a follow-up visit scheduled?
No 5.0 1.6 15.8 0.119
Yes 11.4 2.7 49.0
Number of health-care visits before referral to specialist care
One 2.4 0.7 8.4 < 0.001**
Two 10.6 2.7 42.0
Three or more 17.0 4.1 71.0
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In Finland, with a population of 5.5 million, the man-
agement of HNC is regulated by governmental author-
ities and organized by the public health care system for
all patients and, more importantly, centralized at five
university hospitals. Patients can either seek medical
care from the public PHC centers or from private
medical care centers offering SC. Both sectors, will simi-
larly be able to refer patients to public SC. In public sec-
tor, patient’s care and the referral pattern are similar
throughout the entire country and the health care is al-
most entirely funded by the municipality that the patient
belongs to. Only a small portion is paid by the patient
Table 5 Multivariate linear model for variables predicting patient delay, primary health-care delay, specialist delay, and total delay
(Continued)
Patient delay Primary health-care delay Specialist delay
Geometric
mean
95% CI P
value
Geometric
mean
95% CI P value Geometric
mean
95% CI P
value
Appointment at another hospital
No 47.9 40.2 57.1 0.343
Yes 54.2 42.4 69.2
Treatment modality
Surgery with or without (C)RT 46.6 37.2 58.4 0.141
(C)RT 55.6 46.0 67.4
Treatment intent
Curative 27.2 15.4 47.9 0.191 14.8 7.2 30.5 0.179
Palliative 78.6 14.7 420.7 3.9 0.5 30.9
Bonferroni-corrected P values: *, One vs three or more P < 0.081; **, One vs two P value 0.007, one vs three or more P < 0.002
GP general physician, (C) RT (chemo)radiotheraphy
Table 6 Factors influencing health care-related delay (n = 83 patients)
Number (%) PHCa delay P value Specialist-care delayb P value
Initial place of visit 0.088
General physician, dentist or hospital emergency 71 (85.5) 16.0
Private otolaryngologist 10 (12.0) 1.0
Unknown 2 (2.4)
Was a follow-up visit scheduled? 0.012
No 16 (19.3) 37.5
Yes 65 (78.3) 14.0
Unknown 2 (2.4)
Number of health-care visits before referral to specialist care < 0.001
One 37 (44.6) 1.0
Two 22 (26.5) 20.0
Three or more 16 (19.3) 33.0
Unknown 8 (9.6)
Appointment at other hospital 0.066
No 60 (72.3) 49.0
Yes 23 (27.7) 63.0
Treatment modality 0.112
Surgery with or without adjuvant (chemo-)radiation 30 (36.1) 46.0
(Chemo-)radiation 53 (63.9) 55.0
Treatment intent 0.030
Curative 77 (92.8) 17.0
Palliative 6 (7.2) 0.5
aPHC primary health care
bn = 77 patients
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and the payment limit for any health care services in
Finland is 683 euros during a calendar year, after which
all care is entirely free for the patient. The Finnish Min-
istry of Social Affairs and Health in its 2010 working
group report dictated that the SC delay from HNC diag-
nosis should not exceed 3 weeks [25]. Furthermore,
some other European countries have also assessed guide-
lines for the timely initiation of HNC treatment. Our
findings offer information which can further minimize
any SC delays. Both increased patient awareness and ex-
pedited health care processes warrant continuous devel-
opmental efforts.
Most patients had HPV-associated OPSCC (79%) and
diagnostic time intervals did not differ according to the
p16 status. These findings are in line with a recent
North American retrospective cohort study of 152
OPSCC patients, where 84% of the tumors were HPV
positive. In that study, the median patient and PHC de-
lays were 21 days and 8 days, respectively [26]. Accord-
ing to a recent meta-analysis regarding patients with
oral cancer, the weighted mean patient delay was 80.3
days [27], which is significantly longer than in our study
(median, 30 days; mean, 56 days). In many studies, the
delay data are shown as means, even though patient
delay distribution skews to the right and abruptly chosen
cut-off points are used to divide patients into two or
three delay groups for analysis, which can bias the find-
ings [28–30]. For these reasons, we present our results
as medians and analyzed delay data as continuous
variables.
Symptoms that significantly correlated with a pro-
longed patient delay in univariate analysis consisted of
weight loss and difficulties breathing. It might seem
counterintuitive that such a severe symptom as breath-
ing difficulty does not force patients to seek medical care
immediately. However, in our previous study [22], we re-
ported a similar finding, whereby patients’ interpreta-
tions of breathing difficulty varied. If the patient
reported more than one symptom, the sequence and
time of symptom emergence remained unknown. Pa-
tients might have experienced milder symptoms initially,
and, therefore, postponed seeking medical care.
Patients with a more advanced disease at the time of
diagnosis experienced a shorter patient delay. The het-
erogeneity of malignancies and their varying biological
behavior cause differences in their clinical course. Can-
cers that metastasize rapidly to regional lymph nodes
might cause more notable symptoms and, therefore, may
lead to a shorter patient delay. Slowly growing tumors
without regional lymph node involvement might lead to
a slower progression and the emergence of symptoms
and, thus, lead to a longer delay. This naturally remains
highly speculative, such that our results indicated that a
lump on the neck only shortened the SC delay. However,
among TNM variables, N class emerged as the most
strongly associated with patient delay in a covariate-
adjusted analysis, implying that a lump on the neck
might cause a patient to seek medical care promptly.
Yet, this correlation remained insignificant in our ana-
lyses. Existing literature provides varying results regard-
ing the association between cancer stage and patient
delay [12, 14, 29–32]. Multiple studies on head and neck
tumors show no correlation between patient delay and
tumor size [12, 32, 33]. We chose to use both the UICC
7th and 8th editions in our analysis, because the new
edition was released in the middle of our prospective
data collection, and we wanted to be able to compare
our results with the existing literature and review our
data according to the newest classification. We can as-
sume that the UICC 7th edition for tumor classification
better represents the clinical findings of disease, because
the N classification varies according to the number and
size of metastatic lymph nodes on the ipsilateral side of
the tumor regardless of the HPV status. The UICC 8th
edition focuses more on disease prognosis. In this re-
gard, the UICC 7th edition better associates with factors
and clinical findings influencing patients’ medical care–
seeking behavior, allowing for comparison between the
clinical findings among the two patient groups.
HPV-associated OPSCC carries a better overall and
progression-free survival than HPV-unassociated OPSCC
[3, 7–10]. Patients with HPV-associated OPSCC tend to
have a smaller primary tumor, but more extensive neck
disease [7–9]. A recent study on patients’ initial symptoms
stated that two-thirds of patients with HPV-associated
OPSCC presented with an asymptomatic neck mass as the
initial symptom [34]. Another study showed that among
patients with HPV-unassociated OPSCC, symptoms were
more often related to the primary tumor site, including a
sore throat and dysphagia or odynophagia [35]. Based on
these findings, it seems logical that HPV association would
also impact delays. The baseline characteristics in our pa-
tient cohort agree with those presented in previous stud-
ies, since p16-positive patients were generally younger,
smoked fewer cigarettes, and consumed less alcohol [6, 7].
Remarkably, in a recent study by Carpén et al. [36], smok-
ing was rather common among patients with HPV-
associated OPSCC, since 63% of such patients smoked.
Rather notably, 77% of the patients in our study had HPV-
associated OPSCC, a markedly higher portion than about
a decade ago at our institution [37], a change that mirrors
observations from other Western countries.
Currently, employed or student patients reported a
shorter unadjusted median patient delay compared to
unemployed and retired patients. Other sociodemo-
graphic factors (i.e., sex, age, place of residence) played
no role on patient delay, which agrees with other recent
studies [12, 14, 33, 38, 39]. In Finland, employed
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individuals often have access to occupational health care
in addition to the national public health care system,
which might explain such a difference. However, in a
multivariate analysis, this finding remained insignificant.
The most important factor that emerged affecting
PHC delay involved whether a follow-up visit was sched-
uled during the initial visit to PHC, a finding similar to
our previous study [22]. The correlation between the
number of health care visits and the PHC delay is self-
explanatory, since it takes time to visit a doctor during
multiple appointments. Because the questionnaire was
administrated after the cancer diagnosis, a possibility for
recall bias exists. In order to minimize it, we double-
checked the delay data from hospital records. We found
that the reason for four of the five longest PHC delays
consisted of a false-benign finding on a cytological or
histopathological biopsy. In order to minimize the lon-
gest PHC delays, more education is needed among PHC
doctors to acknowledge the risk of false-benign findings
during such examinations.
Patients receiving palliative treatment typically present
with more extensive disease and more notable symp-
toms. Therefore, we somewhat expected their PHC de-
lays would remain fairly short. The correlation between
longer patient delays among palliative care patients is
more complex, since a longer delay may lead to tumor
growth and disease advancement [12, 19, 40]. But, other
reasons might guide management towards palliative
care, such as a poor overall health, the heavy use of alco-
hol or an unwillingness to commit to the recommended
treatment.
SC delay is multifactorial. After referral to Dept. ORL-
HNS, the patient visits an otorhinolaryngologist – head
and neck surgeon, who performs a clinical exam and
evaluates the need for additional imaging and biopsies.
Because of the multiple steps needed to ensure the best
possible care, some delay is unavoidable. The median
delay from the referral to SC to the initiation of curative
treatment reached 50 days. This delay can be divided
into the time from referral to diagnosis, which amounted
to approximately one-third of that delay and the time
from diagnosis to treatment, which comprised two-
thirds of the total delay. The median treatment delay of
29 days (15 days for surgically treated patients and 37
days for those treated with (C)RT) was similar to a large
American study consisting of 51,655 HNC patients in
which the median treatment delay for patients treated
with surgery, RT and CRT were 17, 31 and 34 days, re-
spectively [15]. At our institution, patients treated surgi-
cally received treatment significantly faster than patients
treated with definitive (C)RT. This additional delay is
partially attributed to all preparatory actions required
before (C) RT, although institutional treatment re-
sources might play a role. Nevertheless, the median
delay of 35 days from diagnosis to the initiation of de-
finitive (C) RT calls for monitoring functions and further
evaluation. These actions remain important to minimiz-
ing any delay in OPSCC management.
Limitations
We acknowledge that our patient cohort remained limited
because of the low incidence of OPSCC, but we gathered
data from all newly diagnosed OPSCC patients treated at
our tertiary care hospital covering a catchment area with a
population of 1.6 million people (almost one third of the
whole country) and 75% of these patients were able and
willing to complete the administrated questionnaire. The
data from the remaining patients were gathered from the
hospital records. Our study setting allowed for structured
and comprehensive data collection. Patients not included
in this study had a generally more advanced disease and
palliative treatment was more prevalent among these pa-
tients, possibly resulting in some selection bias reflected in
the findings. We excluded patients unable to complete the
questionnaire or who did not return it from the analysis,
which is an unavoidable limitation to this kind of study.
The questionnaire was administrated following cancer
diagnosis and, therefore, may have affected patients’ abil-
ities to correctly recall symptom onset.
Conclusions
In total, the patient and management delay for OPSCC
was shorter than expected since most patients were
promptly referred to SC. We found that p16 status did
not affect the delay. The most important factors influen-
cing treatment delays included tumor stage, the number
of different symptoms, and the number of visits to a
doctor before the patient was referred to SC. The treat-
ment delay was significantly longer for patients treated
with definitive (C) RT than for those treated surgically
with or without adjuvant (C)RT. However, the delay in
SC remains multifactorial and requires monitoring by an
institutional quality control system.
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